MA45665B1 - Dérivés d'éthynyle - Google Patents
Dérivés d'éthynyleInfo
- Publication number
- MA45665B1 MA45665B1 MA45665A MA45665A MA45665B1 MA 45665 B1 MA45665 B1 MA 45665B1 MA 45665 A MA45665 A MA 45665A MA 45665 A MA45665 A MA 45665A MA 45665 B1 MA45665 B1 MA 45665B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- ethynyl derivatives
- neuroprotection
- autism
- obsessive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne des composés de formules ia et ib ia ib ou à un sel pharmaceutiquement accepté ou un sel d'addition acide, à un mélange racémique, ou à son énantiomère correspondant et/ou isomère optique et/ou stéréoisomère de celui-ci. Les composés peuvent être utilisés pour le traitement de la maladie de parkinson, de l'anxiété, des vomissements, d'un trouble obsessionnel compulsif, de l'autisme, la neuroprotection, du cancer, de la dépression et du diabète de type 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16179837 | 2016-07-18 | ||
PCT/EP2017/067495 WO2018015235A1 (fr) | 2016-07-18 | 2017-07-12 | Dérivés d'éthynyle |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45665B1 true MA45665B1 (fr) | 2020-11-30 |
Family
ID=56418435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA45665A MA45665B1 (fr) | 2016-07-18 | 2017-07-12 | Dérivés d'éthynyle |
Country Status (31)
Country | Link |
---|---|
US (3) | US20190144458A1 (fr) |
EP (1) | EP3484889B1 (fr) |
JP (1) | JP6936305B2 (fr) |
KR (1) | KR20190026805A (fr) |
CN (1) | CN109476671B (fr) |
AR (1) | AR109075A1 (fr) |
AU (1) | AU2017299083B2 (fr) |
BR (1) | BR112019000314A2 (fr) |
CA (1) | CA3030788A1 (fr) |
CL (1) | CL2019000045A1 (fr) |
CO (1) | CO2018013824A2 (fr) |
CR (1) | CR20190014A (fr) |
DK (1) | DK3484889T3 (fr) |
ES (1) | ES2826389T3 (fr) |
HR (1) | HRP20201615T1 (fr) |
HU (1) | HUE051006T2 (fr) |
IL (1) | IL263884A (fr) |
LT (1) | LT3484889T (fr) |
MA (1) | MA45665B1 (fr) |
MX (1) | MX2019000442A (fr) |
PE (1) | PE20190382A1 (fr) |
PH (1) | PH12019500119A1 (fr) |
PL (1) | PL3484889T3 (fr) |
PT (1) | PT3484889T (fr) |
RS (1) | RS60908B1 (fr) |
RU (1) | RU2745068C2 (fr) |
SG (1) | SG11201811829QA (fr) |
SI (1) | SI3484889T1 (fr) |
TW (1) | TWI729169B (fr) |
WO (1) | WO2018015235A1 (fr) |
ZA (1) | ZA201900113B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2733468T3 (es) | 2015-07-15 | 2019-11-29 | Hoffmann La Roche | Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato |
CN110183456A (zh) * | 2019-07-11 | 2019-08-30 | 河南师范大学 | 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法 |
US11515154B2 (en) * | 2020-10-27 | 2022-11-29 | Applied Materials, Inc. | Selective deposition of a passivation film |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004050039A2 (fr) * | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Urees spirocycliques, compositions les contenant et procedes d'utilisation |
EP1891075B1 (fr) | 2005-05-24 | 2011-10-19 | Merck Serono SA | Derives spiro tricycliques servant de modulateurs de crth2 |
JP2010502617A (ja) | 2006-08-31 | 2010-01-28 | シェーリング コーポレイション | 抗菌物質として有用なヒダントイン誘導体 |
BRPI0812363A2 (pt) | 2007-06-03 | 2015-02-03 | Univ Vanderbilt | Moduladores alostéricos positivos de mglurs de benzamida e métodos de preparação e utilização dos mesmos |
CN102740699A (zh) | 2009-09-04 | 2012-10-17 | 范德比尔特大学 | 用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法 |
US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
HUE025031T2 (en) | 2011-04-26 | 2016-02-29 | Hoffmann La Roche | Ethinyl derivatives as positive allosteric modulators of MGLUR5 |
CA2837312A1 (fr) | 2011-05-26 | 2012-11-29 | Sunovion Pharmaceuticals Inc. | Modulateurs allosteriques du recepteur 5 du glutamate methabotropique et methodes d'utilisation associees |
ES2553449T3 (es) * | 2011-07-06 | 2015-12-09 | Gilead Sciences, Inc. | Compuestos para el tratamiento de VIH |
US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
UA114934C2 (uk) | 2012-10-18 | 2017-08-28 | Ф. Хоффманн-Ля Рош Аг | Похідне етинілу як модулятор активності метаботропного глутаматного рецептора підтипу 5 |
CN104603110B (zh) | 2012-10-18 | 2016-08-31 | 霍夫曼-拉罗奇有限公司 | 作为mGluR5受体活性的调节剂的乙炔基衍生物 |
WO2014124560A1 (fr) | 2013-02-18 | 2014-08-21 | Hua Medicine (Shanghai) Ltd. | Régulateurs de mglur |
UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
DK3049409T3 (en) * | 2013-09-25 | 2017-07-10 | Hoffmann La Roche | ethynyl derivatives |
TWI649310B (zh) | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
PE20161415A1 (es) | 2014-02-25 | 2017-01-06 | Hoffmann La Roche | Derivados de etinilo |
CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
JP6539749B2 (ja) | 2015-03-19 | 2019-07-03 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | mGluR4のモジュレーターとしての3−(4−エチニルフェニル)ヘキサヒドロピリミジン−2,4−ジオン誘導体 |
ES2733468T3 (es) | 2015-07-15 | 2019-11-29 | Hoffmann La Roche | Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato |
US10391998B2 (en) | 2016-11-16 | 2019-08-27 | Ford Global Technologies, Llc | Vehicle systems and methods for reducing electrified vehicle noise, vibration, and harshness |
-
2017
- 2017-07-12 BR BR112019000314-2A patent/BR112019000314A2/pt not_active IP Right Cessation
- 2017-07-12 CN CN201780044455.5A patent/CN109476671B/zh active Active
- 2017-07-12 JP JP2019502162A patent/JP6936305B2/ja active Active
- 2017-07-12 MX MX2019000442A patent/MX2019000442A/es active IP Right Grant
- 2017-07-12 CA CA3030788A patent/CA3030788A1/fr not_active Abandoned
- 2017-07-12 SI SI201730468T patent/SI3484889T1/sl unknown
- 2017-07-12 RU RU2019102757A patent/RU2745068C2/ru active
- 2017-07-12 PE PE2018003348A patent/PE20190382A1/es unknown
- 2017-07-12 WO PCT/EP2017/067495 patent/WO2018015235A1/fr unknown
- 2017-07-12 LT LTEP17742971.9T patent/LT3484889T/lt unknown
- 2017-07-12 MA MA45665A patent/MA45665B1/fr unknown
- 2017-07-12 PT PT177429719T patent/PT3484889T/pt unknown
- 2017-07-12 EP EP17742971.9A patent/EP3484889B1/fr active Active
- 2017-07-12 DK DK17742971.9T patent/DK3484889T3/da active
- 2017-07-12 SG SG11201811829QA patent/SG11201811829QA/en unknown
- 2017-07-12 RS RS20201217A patent/RS60908B1/sr unknown
- 2017-07-12 ES ES17742971T patent/ES2826389T3/es active Active
- 2017-07-12 HU HUE17742971A patent/HUE051006T2/hu unknown
- 2017-07-12 KR KR1020197003025A patent/KR20190026805A/ko active IP Right Grant
- 2017-07-12 PL PL17742971T patent/PL3484889T3/pl unknown
- 2017-07-12 CR CR20190014A patent/CR20190014A/es unknown
- 2017-07-12 AU AU2017299083A patent/AU2017299083B2/en not_active Ceased
- 2017-07-17 AR ARP170101987A patent/AR109075A1/es unknown
- 2017-07-17 TW TW106123741A patent/TWI729169B/zh not_active IP Right Cessation
-
2018
- 2018-12-19 CO CONC2018/0013824A patent/CO2018013824A2/es unknown
- 2018-12-20 IL IL263884A patent/IL263884A/en active IP Right Grant
-
2019
- 2019-01-07 CL CL2019000045A patent/CL2019000045A1/es unknown
- 2019-01-08 ZA ZA2019/00113A patent/ZA201900113B/en unknown
- 2019-01-16 PH PH12019500119A patent/PH12019500119A1/en unknown
- 2019-01-17 US US16/250,278 patent/US20190144458A1/en not_active Abandoned
-
2020
- 2020-05-01 US US16/865,233 patent/US11242349B2/en active Active
- 2020-10-08 HR HRP20201615TT patent/HRP20201615T1/hr unknown
-
2022
- 2022-01-04 US US17/568,530 patent/US20220127275A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42442B1 (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
RU2471781C2 (ru) | Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии | |
MA47368B1 (fr) | N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga | |
MA45665B1 (fr) | Dérivés d'éthynyle | |
MA42341A1 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
MA40993A (fr) | Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 | |
PH12016501100B1 (en) | Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators | |
MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
MA39427A1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
MA43706B1 (fr) | Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité en tant qu'agoniste de taar | |
MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
SA520420382B1 (ar) | مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1 | |
PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
MA38011B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5 | |
MA56186A (fr) | Composés pour le traitement d'une maladie respiratoire | |
MA50036B1 (fr) | Composés de fluoropipéridine utilisés en tant qu'antagonistes purs du récepteur 5-ht6 | |
MA60976B1 (fr) | Dérivés de la phényl-3,4-dihydroisoquinoléine-2(1h)-yl-éthan-1-one comme modulateurs allostériques positifs du récepteur d1 de la dopamine | |
MA53258A (fr) | Composés pour le traitement de la maladie d'alzheimer | |
FR3073842B1 (fr) | Procede de preparation du 1-chloro-3,3,3-trifluoropropene | |
MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam |